Please use this identifier to cite or link to this item:
Title: Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia
Authors: Hussein Kamareddine, Mohammed
Ghosn, Youssef
Tawk, Antonios
Elia, Carlos
Alam, Walid
Makdessi, Joseph
Farhat, Said
Affiliations: Faculty of Medicine 
Faculty of Medicine 
Keywords: CML
Drug delivery systems
Multidrug resistance
Organic nanoparticles
Issue Date: 2019
Publisher: National Library of Medicine
Part of: Technology in cancer research & treatment
Volume: 18
Chronic myeloid leukemia is a myeloproliferative neoplasm that occurs more prominently in the older population, with a peak incidence at ages 45 to 85 years and a median age at diagnosis of 65 years. This disease comprises roughly 15% of all leukemias in adults. It is a clonal stem cell disorder of myeloid cells characterized by the presence of t(9;22) chromosomal translocation, also known as the Philadelphia chromosome, or its byproducts BCR-ABL fusion protein/messenger RNA, leading to the expression of a protein with enhanced tyrosine kinase activity. This fusion protein has become the main therapeutic target in chronic myeloid leukemia therapy, with imatinib displaying superior antileukemic effects, placing it at the forefront of current treatment protocols and displaying great efficacy. Alternatively, nanomedicine and employing nanoparticles as drug delivery systems may represent new approaches in future anticancer therapy. This review focuses primarily on the use of organic nanoparticles aimed at chronic myeloid leukemia therapy in both in vitro and in vivo settings, by going through a thorough survey of published literature. After a brief introduction on the pathogenesis of chronic myeloid leukemia, a description of conventional, first- and second-line, treatment modalities of chronic myeloid leukemia is presented. Finally, some of the general applications of nanostrategies in medicine are presented, with a detailed focus on organic nanocarriers and their constituents used in chronic myeloid leukemia treatment from the literature.
DOI: 10.1177/1533033819879902
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Aug 13, 2022

Record view(s)

checked on Aug 14, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.